Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 5N79Z | SC |
Inappropriate Route of Administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 73-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 5N79Z, expiry date 12-DEC-2026) for prophylaxis. On 30-JAN-2026, the patient received the 1st dose of Arexvy (subcutaneous). On 30-JAN-2026, an unknown time after receiving Arexvy, the patient experienced intramuscular formulation administered by other route (Verbatim: Inappropriate Route of Administration). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK receipt date: 30-JAN-2026 A pharmacist called to get guidance after he administered a dose of Arexvy and immediately realized there was a bubble below the skin of the patient, like if it was administered Subcutaneous instead of the recommended Intramuscular route. The reporter wanted to know if it was considered a valid shot.